This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
Revolutionary technology will further boost OneSource’s scientific services offerings
Subscribe To Our Newsletter & Stay Updated
